The partnership announced at the DFCon Conference Symposium in Los Angeles integrates biologics, remote patient monitoring technology, advanced wound care solutions, and clinically proven mechanical offloading footwear into a single platform called 'Alternative to Amputation: Footwear as a Service (FAAS): A Remote Patient Monitoring Artificial Intelligence Platform'. This collaboration addresses a critical healthcare challenge, as diabetic foot ulcers affect approximately 15% of people with diabetes and represent the primary cause of lower extremity amputations in the United States. Research indicates that between 14% and 24% of individuals with diabetes who develop foot ulcers will ultimately require amputation, highlighting the urgent need for more effective management strategies.
The platform leverages the specialized capabilities of each partner organization. Anderson Medical Supplies provides dedicated patient monitoring clinical services, while AlexiGen contributes its skin graft products. Defender and Sensoria Health offer their Smart Boot and remote patient monitoring services, with the Defender smart boot incorporating Sensoria Health's innovative Sensoria Core and Smart Watch sensor and software technology. This technology is currently being validated in a new NIH R01 funded clinical study conducted by the University of Southern California Keck School of Medicine and Baylor College of Medicine, demonstrating the scientific rigor behind the approach.
The Sensoria Remote Patient Monitoring (RPM) mobile plus cloud software platform enables clinicians to track patients' adherence to physician-prescribed treatment plans in near real-time. This monitoring capability is expected to enhance compliance, which in turn improves the performance of AlexiGen's skin substitute and increases the likelihood of positive patient outcomes. Davide Vigano, CEO and cofounder of Sensoria Health Inc., emphasized the multidisciplinary nature of the effort, stating that reducing amputations requires such collaborative approaches developed over many years.
The Defender smart boot, equipped with Sensoria's technology, represents a significant advancement in quantifying and monitoring patient adherence and activity during diabetic foot ulcer treatment. By offering a comprehensive solution that combines advanced technology with clinical expertise, this partnership has the potential to fundamentally shift outcomes for those at risk of amputation. The FAAS Platform provides a promising alternative to amputation for diabetic patients, potentially transforming the landscape of DFU treatment and improving lives worldwide. As the technology continues to develop and demonstrate efficacy, it could lead to substantial reductions in diabetic foot amputations, thereby improving patient quality of life and decreasing the economic burden of this serious diabetes complication.
